The company, which got started in genomic testing, has quickly expanded its services to include providing Covid-19 testing at businesses and universities. With the new funding, it plans to build infrastructure for more preventive health services.
The partnership builds on an existing relationship between All of Us and Color, which was chosen as one of three genome centers that are responsible for actual genotyping of patient samples.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
As part of a new initiative called DNA10K, more than 10,000 NorthShore patients will gain access to Color's clinical-grade genetic testing and whole genome sequencing.
Here's a look at some of the most intriguing biopharma news developments this week from an investment in a new approach for early diagnosis of Alzheimer's disease to reports highlighting flaws in the FDA's accelerated drug and device approval programs.
Color Genomics' latest test highlights the quandary of genetic testing colliding with value-based care: Is the push to test taking preventive medicine in the wrong direction?